Click here to get full coverage on $DNLI stock is down 11% today. Here's what we see in our data. - Quiver Quantitative

$DNLI stock is down 11% today. Here's what we see in our data.  Quiver Quantitative

$DNLI stock is down 11% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound - Yahoo Finance

Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound  Yahoo Finance

Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound - Yahoo Finance

Click here to get full coverage on Denali Therapeutics (NASDAQ: DNLI) prices $200M equity deal at $17.50 - Stock Titan

Denali Therapeutics (NASDAQ: DNLI) prices $200M equity deal at $17.50  Stock Titan

Denali Therapeutics (NASDAQ: DNLI) prices $200M equity deal at $17.50 - Stock Titan

Click here to get full coverage on Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $30 - 富途牛牛

Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $30  富途牛牛

Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $30 - 富途牛牛

Click here to get full coverage on Wedbush Maintains 'Outperform' Rating for DNLI, Lowers Price Tar - GuruFocus

Wedbush Maintains 'Outperform' Rating for DNLI, Lowers Price Tar  GuruFocus

Wedbush Maintains 'Outperform' Rating for DNLI, Lowers Price Tar - GuruFocus

Click here to get full coverage on Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - Sahm

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants  Sahm

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - Sahm

Click here to get full coverage on Denali Therapeutics slides after launching $200 million share sale - TradingView

Denali Therapeutics slides after launching $200 million share sale  TradingView

Denali Therapeutics slides after launching $200 million share sale - TradingView

Click here to get full coverage on Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment (DNLI) - Seeking Alpha

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment (DNLI)  Seeking Alpha

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment (DNLI) - Seeking Alpha

Click here to get full coverage on BTIG Reiterates Denali Therapeutics (DNLI) Buy Recommendation - Nasdaq

BTIG Reiterates Denali Therapeutics (DNLI) Buy Recommendation  Nasdaq

BTIG Reiterates Denali Therapeutics (DNLI) Buy Recommendation - Nasdaq

Click here to get full coverage on Marshall Wace LLP Sells 783,172 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat

Marshall Wace LLP Sells 783,172 Shares of Denali Therapeutics Inc. $DNLI  MarketBeat

Marshall Wace LLP Sells 783,172 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat

Click here to get full coverage on Top Pre‑Market Losers Today (December 10, 2025): AFJK, CBRL, DNLI & AEG Lead Early Declines Before the Bell - ts2.tech

Top Pre‑Market Losers Today (December 10, 2025): AFJK, CBRL, DNLI & AEG Lead Early Declines Before the Bell  ts2.tech

Top Pre‑Market Losers Today (December 10, 2025): AFJK, CBRL, DNLI & AEG Lead Early Declines Before the Bell - ts2.tech

Click here to get full coverage on Technical Reactions to DNLI Trends in Macro Strategies - news.stocktradersdaily.com

Technical Reactions to DNLI Trends in Macro Strategies  news.stocktradersdaily.com

Technical Reactions to DNLI Trends in Macro Strategies - news.stocktradersdaily.com

Click here to get full coverage on Denali Therapeutics (NASDAQ: DNLI) plans $200M stock, pre-funded warrant sale with $30M option - Stock Titan

Denali Therapeutics (NASDAQ: DNLI) plans $200M stock, pre-funded warrant sale with $30M option  Stock Titan

Denali Therapeutics (NASDAQ: DNLI) plans $200M stock, pre-funded warrant sale with $30M option - Stock Titan

Click here to get full coverage on H.C. Wainwright Reiterates “Buy” Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results - Yahoo Finance

H.C. Wainwright Reiterates “Buy” Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results  Yahoo Finance

H.C. Wainwright Reiterates “Buy” Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results - Yahoo Finance

Click here to get full coverage on Denali Therapeutics Inc. Announces $200 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative

Denali Therapeutics Inc. Announces $200 Million Public Offering of Common Stock and Pre-Funded Warrants  Quiver Quantitative

Denali Therapeutics Inc. Announces $200 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative

Click here to get full coverage on Denali’s Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI) - Yahoo Finance

Denali’s Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI)  Yahoo Finance

Denali’s Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI) - Yahoo Finance

Click here to get full coverage on DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 - Yahoo Finance

DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26  Yahoo Finance

DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 - Yahoo Finance

Click here to get full coverage on Denali Therapeutics (DNLI): Evaluating Valuation Disconnect Despite Lack of Major News - Yahoo Finance

Denali Therapeutics (DNLI): Evaluating Valuation Disconnect Despite Lack of Major News  Yahoo Finance

Denali Therapeutics (DNLI): Evaluating Valuation Disconnect Despite Lack of Major News - Yahoo Finance

Click here to get full coverage on FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months - Yahoo Finance

FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months  Yahoo Finance

FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months - Yahoo Finance

Click here to get full coverage on DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug - Zacks Investment Research

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug  Zacks Investment Research

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug - Zacks Investment Research

Click here to get full coverage on Denali: Regulatory Delay Is A Strategic Opportunity (NASDAQ:DNLI) - Seeking Alpha

Denali: Regulatory Delay Is A Strategic Opportunity (NASDAQ:DNLI)  Seeking Alpha

Denali: Regulatory Delay Is A Strategic Opportunity (NASDAQ:DNLI) - Seeking Alpha

Click here to get full coverage on Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? - Yahoo Finance

Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?  Yahoo Finance

Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? - Yahoo Finance

Click here to get full coverage on Denali Therapeutics (DNLI): Reassessing Valuation After $275m Royalty Deal and Hunter Syndrome Launch Progress - Sahm

Denali Therapeutics (DNLI): Reassessing Valuation After $275m Royalty Deal and Hunter Syndrome Launch Progress  Sahm

Denali Therapeutics (DNLI): Reassessing Valuation After $275m Royalty Deal and Hunter Syndrome Launch Progress - Sahm

Click here to get full coverage on New Analyst Forecast: $DNLI Given $31 Price Target - Quiver Quantitative

New Analyst Forecast: $DNLI Given $31 Price Target  Quiver Quantitative

New Analyst Forecast: $DNLI Given $31 Price Target - Quiver Quantitative

Click here to get full coverage on Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy - Yahoo Finance

Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy  Yahoo Finance

Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy - Yahoo Finance

Click here to get full coverage on Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $31 - 富途牛牛

Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $31  富途牛牛

Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $31 - 富途牛牛

Click here to get full coverage on Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants  GlobeNewswire

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire

Click here to get full coverage on Denali Therapeutics dips after pricing $200M equity offering - MSN

Denali Therapeutics dips after pricing $200M equity offering  MSN

Denali Therapeutics dips after pricing $200M equity offering - MSN

Click here to get full coverage on DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review - Yahoo Finance

DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review  Yahoo Finance

DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review - Yahoo Finance

Click here to get full coverage on Denali Enters Into a $275M Funding Deal With Royalty Pharma - Zacks Investment Research

Denali Enters Into a $275M Funding Deal With Royalty Pharma  Zacks Investment Research

Denali Enters Into a $275M Funding Deal With Royalty Pharma - Zacks Investment Research

Click here to get full coverage on Denali Therapeutics Announces Board and Executive Leadership Updates - Yahoo Finance

Denali Therapeutics Announces Board and Executive Leadership Updates  Yahoo Finance

Denali Therapeutics Announces Board and Executive Leadership Updates - Yahoo Finance

Click here to get full coverage on Will Denali Therapeutics' (DNLI) US$275 Million Tividenofusp Royalty Deal Change Its Investment Narrative? - simplywall.st

Will Denali Therapeutics' (DNLI) US$275 Million Tividenofusp Royalty Deal Change Its Investment Narrative?  simplywall.st

Will Denali Therapeutics' (DNLI) US$275 Million Tividenofusp Royalty Deal Change Its Investment Narrative? - simplywall.st

Click here to get full coverage on Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth - Yahoo Finance

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth  Yahoo Finance

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth - Yahoo Finance

Click here to get full coverage on Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI) - Seeking Alpha

Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI)  Seeking Alpha

Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI) - Seeking Alpha

Click here to get full coverage on Denali Therapeutics hosts investor day, updates pipeline - MSN

Denali Therapeutics hosts investor day, updates pipeline  MSN

Denali Therapeutics hosts investor day, updates pipeline - MSN

Click here to get full coverage on Denali Therapeutics Announces $200M Public Offering - TipRanks

Denali Therapeutics Announces $200M Public Offering  TipRanks

Denali Therapeutics Announces $200M Public Offering - TipRanks

Click here to get full coverage on Denali Therapeutics (DNLI): Evaluating Valuation Following Major Executive Leadership Changes - Sahm

Denali Therapeutics (DNLI): Evaluating Valuation Following Major Executive Leadership Changes  Sahm

Denali Therapeutics (DNLI): Evaluating Valuation Following Major Executive Leadership Changes - Sahm

Click here to get full coverage on FDA Fast-Tracks Denali's Breakthrough Hunter Syndrome Drug as Pipeline Expands - Stock Titan

FDA Fast-Tracks Denali's Breakthrough Hunter Syndrome Drug as Pipeline Expands  Stock Titan

FDA Fast-Tracks Denali's Breakthrough Hunter Syndrome Drug as Pipeline Expands - Stock Titan

Click here to get full coverage on What's Going On With Denali Therapeutics Stock Friday? - Denali Therapeutics (NASDAQ:DNLI) - Benzinga

What's Going On With Denali Therapeutics Stock Friday? - Denali Therapeutics (NASDAQ:DNLI)  Benzinga

What's Going On With Denali Therapeutics Stock Friday? - Denali Therapeutics (NASDAQ:DNLI) - Benzinga

Click here to get full coverage on First Week of June 2026 Options Trading For Denali Therapeutics (DNLI) - Nasdaq

First Week of June 2026 Options Trading For Denali Therapeutics (DNLI)  Nasdaq

First Week of June 2026 Options Trading For Denali Therapeutics (DNLI) - Nasdaq

Click here to get full coverage on Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN

Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants  MSN

Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN

Click here to get full coverage on Denali Therapeutics (DNLI): How Does Its Valuation Stack Up After Recent Share Price Gains? - Sahm

Denali Therapeutics (DNLI): How Does Its Valuation Stack Up After Recent Share Price Gains?  Sahm

Denali Therapeutics (DNLI): How Does Its Valuation Stack Up After Recent Share Price Gains? - Sahm

Click here to get full coverage on Should You Reconsider Denali Therapeutics After This Year’s Collaboration and FDA News? - simplywall.st

Should You Reconsider Denali Therapeutics After This Year’s Collaboration and FDA News?  simplywall.st

Should You Reconsider Denali Therapeutics After This Year’s Collaboration and FDA News? - simplywall.st

Click here to get full coverage on Can Denali Therapeutics (DNLI)’s New Leadership Steady the Narrative Amid Mounting Losses? - Sahm

Can Denali Therapeutics (DNLI)’s New Leadership Steady the Narrative Amid Mounting Losses?  Sahm

Can Denali Therapeutics (DNLI)’s New Leadership Steady the Narrative Amid Mounting Losses? - Sahm

Click here to get full coverage on Denali Therapeutics prices stock offering at $17.50 per share - MSN

Denali Therapeutics prices stock offering at $17.50 per share  MSN

Denali Therapeutics prices stock offering at $17.50 per share - MSN

Click here to get full coverage on Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025? - Yahoo Finance

Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025?  Yahoo Finance

Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025? - Yahoo Finance

Click here to get full coverage on First Brain-Penetrating Hunter Syndrome Treatment in 20 Years Gets FDA Priority Review - Stock Titan

First Brain-Penetrating Hunter Syndrome Treatment in 20 Years Gets FDA Priority Review  Stock Titan

First Brain-Penetrating Hunter Syndrome Treatment in 20 Years Gets FDA Priority Review - Stock Titan

Click here to get full coverage on Denali Enters Into a $275M Funding Deal With Royalty Pharma - WV News

Denali Enters Into a $275M Funding Deal With Royalty Pharma  WV News

Denali Enters Into a $275M Funding Deal With Royalty Pharma - WV News

Click here to get full coverage on BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛

BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32  富途牛牛

BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛

Click here to get full coverage on DNLI January 2026 Options Begin Trading - Nasdaq

DNLI January 2026 Options Begin Trading  Nasdaq

DNLI January 2026 Options Begin Trading - Nasdaq

Click here to get full coverage on BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $29 - 富途牛牛

BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $29  富途牛牛

BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $29 - 富途牛牛

Click here to get full coverage on Denali Enters Into a $275M Funding Deal With Royalty Pharma - Prime Publishers, Inc.

Denali Enters Into a $275M Funding Deal With Royalty Pharma  Prime Publishers, Inc.

Denali Enters Into a $275M Funding Deal With Royalty Pharma - Prime Publishers, Inc.

Click here to get full coverage on Denali Therapeutics Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - simplywall.st

Denali Therapeutics Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution  simplywall.st

Denali Therapeutics Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - simplywall.st

Click here to get full coverage on Denali Therapeutics secures $275M royalty funding deal - MSN

Denali Therapeutics secures $275M royalty funding deal  MSN

Denali Therapeutics secures $275M royalty funding deal - MSN

Click here to get full coverage on Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential - Yahoo Finance

Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential  Yahoo Finance

Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential - Yahoo Finance

Click here to get full coverage on Why You Shouldn't Bet Against Denali (DNLI) Stock - Yahoo Finance

Why You Shouldn't Bet Against Denali (DNLI) Stock  Yahoo Finance

Why You Shouldn't Bet Against Denali (DNLI) Stock - Yahoo Finance

Click here to get full coverage on Denali Therapeutics gets FDA review extension for tividenofusp alfa - Seeking Alpha

Denali Therapeutics gets FDA review extension for tividenofusp alfa  Seeking Alpha

Denali Therapeutics gets FDA review extension for tividenofusp alfa - Seeking Alpha

Click here to get full coverage on Denali Enters Into a $275M Funding Deal With Royalty Pharma - cnhinews.com

Denali Enters Into a $275M Funding Deal With Royalty Pharma  cnhinews.com

Denali Enters Into a $275M Funding Deal With Royalty Pharma - cnhinews.com

Click here to get full coverage on Denali Therapeutics announces board and leadership changes - Investing.com

Denali Therapeutics announces board and leadership changes  Investing.com

Denali Therapeutics announces board and leadership changes - Investing.com

Click here to get full coverage on DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Yahoo Finance

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up  Yahoo Finance

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Yahoo Finance

Click here to get full coverage on Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI) - Seeking Alpha

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI)  Seeking Alpha

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI) - Seeking Alpha

Click here to get full coverage on Denali Therapeutics Announces Extension of FDA Review Timeline for Tividenofusp Alfa in Hunter Syndrome Treatment - Quiver Quantitative

Denali Therapeutics Announces Extension of FDA Review Timeline for Tividenofusp Alfa in Hunter Syndrome Treatment  Quiver Quantitative

Denali Therapeutics Announces Extension of FDA Review Timeline for Tividenofusp Alfa in Hunter Syndrome Treatment - Quiver Quantitative

Click here to get full coverage on How strong is DNLI stock revenue growth - 2025 Growth vs Value & Advanced Swing Trade Entry Plans - moha.gov.vn

How strong is DNLI stock revenue growth - 2025 Growth vs Value & Advanced Swing Trade Entry Plans  moha.gov.vn

How strong is DNLI stock revenue growth - 2025 Growth vs Value & Advanced Swing Trade Entry Plans - moha.gov.vn

Click here to get full coverage on Denali Therapeutics Announces FDA Review Extension Of BLA For Tividenofusp Alfa - TradingView

Denali Therapeutics Announces FDA Review Extension Of BLA For Tividenofusp Alfa  TradingView

Denali Therapeutics Announces FDA Review Extension Of BLA For Tividenofusp Alfa - TradingView

Click here to get full coverage on FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate - Sahm

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate  Sahm

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate - Sahm

Click here to get full coverage on Denali therapeutics’ Ho Carole sells $52k in stock - Investing.com

Denali therapeutics’ Ho Carole sells $52k in stock  Investing.com

Denali therapeutics’ Ho Carole sells $52k in stock - Investing.com

Click here to get full coverage on Denali Therapeutics Faces FDA Review Extension - TipRanks

Denali Therapeutics Faces FDA Review Extension  TipRanks

DNLI

Price Chart

Key Statistics

Technicals

About DNLI

Latest News

$DNLI stock is down 11% today. Here's what we see in our data. - Quiver Quantitative

Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound - Yahoo Finance

Denali Therapeutics (NASDAQ: DNLI) prices $200M equity deal at $17.50 - Stock Titan

Advanced Charts

Top Gainers

Top Losers